10.1007/s40204-017-0077-7

New formulation and approach for mucoadhesive buccal film of rizatriptan benzoate

Show Details XML HTML PDF
  • Sahar Salehi1,
  • Soheil Boddohi*1,
  1. Department of Biomedical Engineering, Faculty of Chemical Engineering, Tarbiat Modares University, Tehran, IR
Cover Image

Published in Issue 2017-11-06

How to Cite

Salehi, S., & Boddohi, S. (2017). New formulation and approach for mucoadhesive buccal film of rizatriptan benzoate. Progress in Biomaterials, 6(4 (December 2017). https://doi.org/10.1007/s40204-017-0077-7
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Abstract Mucoadhesive buccal film is developed as a promising dosage form, which has prominent advantages because of drug delivery through buccal mucosa. New formulation of buccal films containing rizatriptan benzoate (RB) was prepared by solvent casting method using various concentrations of hydroxypropyl methylcellulose (HPMC K4M), polyvinyl alcohol (PVA), polyethylene oxide (PEO), glycerol, stevia, and goat buccal mucosa used as a model membrane. In this work, the effect of polymers and plasticizer concentrations on drug release profile, disintegration and dissolution time, mechanical properties, and mucoadhesive characteristics of films was studied. Scanning electron microscopy analysis revealed uniform distribution of RB in film formulations. Chemical compounds and thermal analysis of the films were studied by Fourier transform infrared spectroscopy and differential scanning calorimetry, respectively. The buccal films produced were uniform in drug content and thickness. All formulations have in vitro release of 98–102% between 40 and 80 min. Also ex vivo mucoadhesion strength was in the range of 0.205 ± 0.035 to 0.790 ± 0.014 N for all formulations. A formulation consisting RB (50 mg), HPMC K4M, PVA, and PEO (63 mg), glycerol (1.5 ml), stevia (5 mg) was selected as our optimum composition. More satisfactory results were obtained in terms of disintegration and dissolution time, mechanical properties, and mucoadhesive characteristics. In addition, it showed about 99.89% RB released in 45 min. The results suggest that RB-loaded mucoadhesive buccal films could be a potential candidate to achieve optimum drug release for effective treatment of migraine.

Keywords

  • Mucoadhesive buccal film,
  • Rizatriptan benzoate,
  • Solvent casting,
  • In vitro release,
  • Ex vivo mucoadhesion strength
HTML PDF

References

  1. Abd El Azim et al. (2015) Liposomal buccal mucoadhesive film for improved delivery and permeation of water-soluble vitamins (pp. 78-85) https://doi.org/10.1016/j.ijpharm.2015.04.052
  2. Adhikari et al. (2010) Formulation and evaluation of buccal patches for delivery of atenolol (pp. 1038-1044) https://doi.org/10.1208/s12249-010-9459-z
  3. Aframian et al. (2006) The distribution of oral mucosal ph values in healthy saliva secretors (pp. 420-423) https://doi.org/10.1111/j.1601-0825.2005.01217.x
  4. Avachat et al. (2013) Development and evaluation of tamarind seed xyloglucan-based mucoadhesive buccal films of rizatriptan benzoate (pp. 537-542) https://doi.org/10.1016/j.carbpol.2012.08.062
  5. Bahri-Najafi et al. (2014) Preparation and pharmaceutical evaluation of glibenclamide slow release mucoadhesive buccal film (pp. 213-223)
  6. Bianchi et al. (2011) Evaluation of the solubility of the HPMC: PVA blends in biological fluids in vitro (pp. 166-171) https://doi.org/10.1590/S1516-14392011005000033
  7. Borges et al. (2015) Oral films: current status and future perspectives: I—galenical development and quality attributes (pp. 1-19) https://doi.org/10.1016/j.jconrel.2015.03.006
  8. Buanz et al. (2015) Ink-jet printing versus solvent casting to prepare oral films: effect on mechanical properties and physical stability (pp. 611-618) https://doi.org/10.1016/j.ijpharm.2014.12.032
  9. Chaudhary et al. (2013) Development and optimization of fast dissolving oro-dispersible films of granisetron hcl using Box–Behnken statistical design (pp. 193-201) https://doi.org/10.1016/j.bfopcu.2013.05.002
  10. Dixit and Puthli (2009) Oral strip technology: overview and future potential (pp. 94-107) https://doi.org/10.1016/j.jconrel.2009.06.014
  11. Dungarwal and Patil (2016) Development of orodispersible tablets of taste masked rizatriptan benzoate using hydroxypropyl β cyclodextrin (pp. 537-545) https://doi.org/10.1007/s40005-016-0240-5
  12. El-Samaligy et al. (2004) Formulation and evaluation of diclofenac sodium buccoadhesive discs (pp. 27-39) https://doi.org/10.1016/j.ijpharm.2004.07.033
  13. Gilmore and Michael (2011) Treatment of acute migraine headache (pp. 271-280)
  14. Irfan et al. (2016) Orally disintegrating films: a modern expansion in drug delivery system (pp. 537-546) https://doi.org/10.1016/j.jsps.2015.02.024
  15. Karki et al. (2016) Thin films as an emerging platform for drug delivery (pp. 559-574) https://doi.org/10.1016/j.ajps.2016.05.004
  16. Kathpalia and Gupte (2013) An introduction to fast dissolving oral thin film drug delivery systems: a review (pp. 667-684) https://doi.org/10.2174/156720181006131125150249
  17. Khan et al. (2016) Functional physico-chemical, ex vivo permeation and cell viability characterization of omeprazole loaded buccal films for paediatric drug delivery (pp. 217-626) https://doi.org/10.1016/j.ijpharm.2016.01.045
  18. Krampe et al. (2016) Oromucosal film preparations: points to consider for patient centricity and manufacturing processes (pp. 493-506) https://doi.org/10.1517/17425247.2016.1118048
  19. Kristoffersen and Lundqvist (2014) Medication-overuse headache: epidemiology, diagnosis and treatment (pp. 87-99) https://doi.org/10.1177/2042098614522683
  20. Kumria et al. (2016) Buccal films of prednisolone with enhanced bioavailability (pp. 471-478) https://doi.org/10.3109/10717544.2014.920058
  21. Láinez (2006) Rizatriptan in the treatment of migraine (pp. 247-259) https://doi.org/10.2147/nedt.2006.2.3.247
  22. Lauritzen (1994) Pathophysiology of the migraine aura the spreading depression theory (pp. 199-210) https://doi.org/10.1093/brain/117.1.199
  23. Liew et al. (2012) Characterization of oral disintegrating film containing donepezil for alzheimer disease (pp. 134-142) https://doi.org/10.1208/s12249-011-9729-4
  24. Lopez et al. (2015) Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms (pp. 1727-1740) https://doi.org/10.1517/17425247.2015.1060218
  25. Mahesh et al. (2010) Development of taste masked fast disintegrating films of levocetirizine dihydrochloride for oral use (pp. 21-27) https://doi.org/10.2174/156720110790396454
  26. Mathiowitz (1999) Wiley
  27. Merck and Co. I (2013) Maxalt (rizatriptan benzoate) tablets and maxalt-mlt (rizatriptan benzoate) orally disintegrating tablets prescribing information. Whitehouse Station, NJ
  28. Montenegro-Nicolini and Morales (2017) Overview and future potential of buccal mucoadhesive films as drug delivery systems for biologics (pp. 3-14) https://doi.org/10.1208/s12249-016-0525-z
  29. Morales et al. (2017) Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes (pp. 652-668) https://doi.org/10.1208/s12248-017-0054-z
  30. Patel et al. (2007) Formulation, evaluation, and comparison of bilayered and multilayered mucoadhesive buccal devices of propranolol hydrochloride (pp. E147-E154) https://doi.org/10.1208/pt0801022
  31. Peh and Wong (1999) Polymeric films as vehicle for buccal delivery: swelling, mechanical, and bioadhesive properties (pp. 53-61)
  32. Rana and Murthy (2013) Formulation and evaluation of mucoadhesive buccal films impregnated with carvedilol nanosuspension: a potential approach for delivery of drugs having high first-pass metabolism (pp. 224-235) https://doi.org/10.3109/10717544.2013.779331
  33. Russo et al. (2016) A focus on mucoadhesive polymers and their application in buccal dosage forms (pp. 113-125) https://doi.org/10.1016/j.jddst.2015.06.016
  34. Rustemkyzy et al. (2015) Preparation and characterization of ultrarapidly dissolving orodispersible films for treating and preventing iodine deficiency in the pediatric population (pp. 9831-9838) https://doi.org/10.1021/acs.jafc.5b03953
  35. Salamat-Miller et al. (2005) The use of mucoadhesive polymers in buccal drug delivery (pp. 1666-1691) https://doi.org/10.1016/j.addr.2005.07.003
  36. Sattar et al. (2014) Oral transmucosal drug delivery–current status and future prospects (pp. 498-506) https://doi.org/10.1016/j.ijpharm.2014.05.043
  37. Scarpa et al. (2017) Orodispersible films: towards drug delivery in special populations (pp. 327-335) https://doi.org/10.1016/j.ijpharm.2017.03.018
  38. Shanker et al. (2009) Formulation and evaluation of bioadhesive buccal drug delivery of tizanidine hydrochloride tablets (pp. 530-539) https://doi.org/10.1208/s12249-009-9241-2
  39. Shiledar et al. (2014) Formulation and in vitro evaluation of xanthan gum-based bilayered mucoadhesive buccal patches of zolmitriptan (pp. 1234-1242) https://doi.org/10.1016/j.carbpol.2013.10.072
  40. Siepmann et al. (2011) Springer
  41. Silva et al. (2015) Mucoadhesive oral films: the potential for unmet needs (pp. 537-551) https://doi.org/10.1016/j.ijpharm.2015.08.038
  42. U.S. Pharmacopeia (2011) The united states pharmacopeial convention. In: Uniformity of dosage units. United States of America
  43. Vidyadhara et al. (2015) Formulation of rizatriptan benzoate fast dissolving buccal films by emulsion evaporation technique (pp. 101-106) https://doi.org/10.4103/2230-973X.153387
  44. Visser et al. (1996) Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/us rizatriptan study group (pp. 1132-1137) https://doi.org/10.1001/archneur.1996.00550110072014
  45. Wang et al. (2007) Psychiatric comorbidity and suicide risk in adolescents with chronic daily headache (pp. 1468-1473) https://doi.org/10.1212/01.wnl.0000260607.90634.d6